XOMA Royalty Corp (NASDAQ: XOMA)

XOMA Royalty Corp specializes in acquiring and managing intellectual property assets, particularly patents and royalty agreements related to biopharmaceutical products. The company operates within the biotechnology and pharmaceutical sectors, focusing on generating revenue through royalties from licensed technologies and products developed by its partners. Its business model centers on leveraging its extensive patent portfolio to secure licensing agreements and milestone payments, thereby monetizing its intellectual property without direct involvement in manufacturing or commercialization.

The company generates revenue primarily through royalties derived from licensed patents and milestone payments from its partners. Key products and technologies in its portfolio include OJEMDA, a therapeutic developed by Day One Biopharmaceuticals, and various other biopharmaceutical innovations licensed to companies such as Moderna, Janssen, and Pfizer. XOMA Royalty Corp's customer base consists of biotechnology and pharmaceutical firms seeking to license its intellectual property for drug development and commercialization.

• Biopharmaceutical Licensing: XOMA Royalty Corp's core business involves licensing its patented technologies to biopharmaceutical companies. Key products in this segment include OJEMDA, a therapeutic developed by Day One Biopharmaceuticals, and other innovations licensed to partners like Moderna, Janssen, and Pfizer. The company caters to the biotechnology and pharmaceutical industries, providing them with access to proprietary technologies for drug development and commercialization.

XOMA Royalty Corp holds a strategic position in the biopharmaceutical industry by focusing on intellectual property management and royalty generation. The company's competitive advantages include a robust patent portfolio, strategic partnerships with leading biopharmaceutical firms, and a business model that minimizes operational risks by outsourcing development and commercialization to its partners. Key competitors in the intellectual property licensing space include other royalty-focused biopharmaceutical companies and patent management firms.

The company's partners and licensees, such as Day One Biopharmaceuticals, Moderna, Janssen, and Pfizer, form the backbone of its revenue model. These partnerships enable XOMA Royalty Corp to monetize its intellectual property through licensing agreements and milestone payments, ensuring a steady stream of income from the biopharmaceutical sector.